Navigation Links
Prometheus Launches Next Generation IBD Diagnostic Test
Date:10/24/2011

SAN DIEGO, Oct. 24, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the commercial launch of its proprietary PROMETHEUS® IBD sgi Diagnostic™ test. The PROMETHEUS IBD sgi Diagnostic is Prometheus' 4th-generation IBD diagnostic test and the first and only test to combine serologic, genetic, and inflammation markers, hence "sgi", in the proprietary Smart Diagnostic Algorithm for added diagnostic clarity.  

This novel diagnostic test represents a significant advance in the Prometheus Inflammatory Bowel Disease (IBD) franchise of diagnostic and prognostic tests and complements the innovative PROMETHEUS® Crohn's Prognostic.  PROMETHEUS IBD sgi Diagnostic aids healthcare providers in differentiating IBD vs non-IBD, and Crohn's disease (CD) vs. ulcerative colitis (UC), in one comprehensive blood test. Evidence suggests IBD is primarily caused by a deregulated mucosal inflammatory response to intestinal bacteria in genetically susceptible individuals.

This new test will replace the currently available PROMETHEUS® IBD Serology 7 (except in New York where it is pending approval by the NY Department of Health).  

"By now combining three important components strongly associated with IBD, serology (antibodies to bacteria), genetics, and inflammation markers, we believe this novel test represents a significant improvement in helping physicians diagnose their patients with suspected IBD," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "This new test demonstrates almost 20% relative improvement in differentiating CD versus UC as compared to our prior test."

About IBD

IBD, including Crohn's disease and ulcerative colitis, is a chronic inflammatory condition of the intestinal tract. Symptoms of the disease may include diarrhea, abdominal pain, fever and rectal bleeding. Patients may require long-term medical care, including hospitalizations, surgeries and therapeutics. The condition can be difficult to diagnose and manage clinically while consuming a substantial amount of healthcare resources in terms of physician time, procedures and medications. Approximately 1.4 million Americans suffer from IBD.  

About Prometheus

Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with more targeted solutions to optimize care for their patients. Prometheus has become part of Nestle Health Science in July 2011.  Prometheus' corporate offices are located in San Diego, California. For more information about Prometheus, please visit www.prometheuslabs.com.

About Nestle Health Science

Nestle Health Science, a fully-owned subsidiary of Nestle S.A., is operational since January 1, 2011 and has worldwide headquarters in Lutry, Switzerland. Nestle Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. For more information about Nestle Health Science, please visit www.nestlehealthscience.com.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prometheus and the Medco Research Institute® to Evaluate the Use of Prometheus Thiopurine Metabolite Testing for Optimizing Treatment of Inflammatory Bowel Disease Patients
2. Prometheus Announces Agreement to be Acquired by Nestle Health Science
3. Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®
4. Prometheus Highlights Record Performance in 2010
5. Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis
6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
7. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
8. Prometheus Launches ProOnc Dx Cancer Diagnostics
9. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
10. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
11. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... July 28, 2017 EnvoyHealth, a Diplomat company, has ... program for CleverCap LITE, a technology designed to improve ... deliver innovative health technology solutions and services that help ... CleverCap LITE offers medication monitoring and ... cover: Records date ...
(Date:7/27/2017)... 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... the second-quarter 2017 and updated financial guidance for the ... 2017 Highlights Reported net sales of ... prior-year quarter. Net sales at constant currency (organic) grew ... was $0.51, compared to $0.60 in the prior-year quarter. ...
(Date:7/26/2017)... SINGAPORE , July 27, 2017  Radium Medical Aesthetics, a ... LASEMD, designed to delay aging by effectively addressing several skin conditions ... the skin to become rougher and more fragile. The skin becomes ... the unavoidable exposure to the harmful UV rays from the sun ... hyperpigmentation. ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... 18, 2017 , ... More than 20,000 pairs of shoes made their way ... an ambitious venture that conjoined the passions of an NBA star, a Liberty University ... community. These shoes will save lives from the rampant infections transmitted through the soil. ...
(Date:8/18/2017)... New York, NY (PRWEB) , ... August 18, ... ... summer’s edition of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and ... today’s resources available for individuals with hearing impairments and shares the latest innovations ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston area ... Texas, is launching a regional charity effort to provide publicity assistance and generate ... Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that has ...
(Date:8/18/2017)... ... 18, 2017 , ... “Emotions are sacred, valid, honored, encouraged. This is the ... company Generation Mindful. To help change the mindset of parents and educators from punitive ... created the Time-In Toolkit, which launched on Kickstarter 3 weeks ago and fully funded ...
(Date:8/18/2017)... Vermont (PRWEB) , ... August 18, 2017 , ... ... phone numbers and call tracking and monitoring solutions, announced today the launch of ... site include a modern navigation and aesthetic, fully responsive design, and an enhanced ...
Breaking Medicine News(10 mins):